Search company, investor...
Neurelis company logo


Founded Year



Loan | Alive

Total Raised


Last Raised

$65M | 2 yrs ago

About Neurelis

Neurelis is a specialty pharmaceutical company that devleops and commercializes product candidates for epilepsy and the broader central nervous system (CNS) market.

Headquarters Location

3430 Carmel Mountain Road, Suite 300

San Diego, California, 92121,

United States


Missing: Neurelis's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Neurelis's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Neurelis

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Neurelis is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Neurelis Patents

Neurelis has filed 6 patents.

The 3 most popular patent topics include:

  • Benzodiazepines
  • Hypnotics
  • Lactams
patents chart

Application Date

Grant Date


Related Topics




Sedatives, Lactams, Benzodiazepines, Anxiolytics, Hypnotics


Application Date


Grant Date



Related Topics

Sedatives, Lactams, Benzodiazepines, Anxiolytics, Hypnotics



Latest Neurelis News


Mar 2, 2023

News provided by Share this article Share this article 'Give Seizures the Sprayer', marketing campaign led by Beth Henriksen, Director of Marketing, Neurelis, Inc., wins the 2023 PM360 Pharma Choice Multichannel Gold Award SAN DIEGO, March 2, 2023 /PRNewswire/ -- Neurelis, Inc. is proud to announce the 'Give Seizures the Sprayer' marketing campaign for VALTOCO® (diazepam nasal spray) CIV has won a 2023 PM360 Pharma Choice Multichannel Gold Award. PM360, a leading health and life sciences marketing industry trade magazine, established the Pharma Choice Awards to honor the year's best creative campaigns and marketing initiatives from the life sciences industry. Based on popular vote from the publication's readers, voters are asked to assess submissions based on content, format, imagination, influence on the industry, audience impact, and overall quality. More than 8,500 votes were cast for the 13th Annual PM360 Pharma Choice Awards . "This award is an incredible honor, notably as it is voted upon by peers and fellow marketers. We all understand the work that goes into campaign development and the goal to be both differentiated and authentic," said Beth Henriksen, Director of Marketing, Neurelis. "The campaign was inspired by the shared frustration people with epilepsy and their care partners experience when their daily lives are disrupted by seizure clusters. We channeled that energy into this campaign to spark conversation and bring awareness to VALTOCO as a treatment option." Created in collaboration with Fingerpaint Marketing, a full-service advertising agency that specializes in creating analytics-enabled integrated solutions for biopharma, the 'Give Seizures the Sprayer' campaign reflects the relief and spirit VALTOCO evokes in people with epilepsy who experience seizure clusters and their care partners. With the goal of empowering people to stand up to seizure clusters, the messaging shined through. "At Neurelis, we partner with those impacted by epilepsy to foster confidence in a rescue therapy that can help get them back to their daily activities," said Founder and CEO of Neurelis, Craig Chambliss. "Empowering people with epilepsy to manage their seizure clusters and have a better quality of life is at the heart of everything we do." VALTOCO is the most prescribed FDA-approved product for short-term treatment of seizure clusters in adult and pediatric patients 6 years of age and older. VALTOCO was approved by the U.S. Food and Drug Administration (FDA) on Jan. 10, 2020. About Neurelis Neurelis, Inc., is a commercial-stage neuroscience company focused on the development and commercialization of therapeutics for the treatment of epilepsy and orphan neurologic disorders characterized by high unmet medical need. In 2020, the FDA approved Neurelis' VALTOCO® (diazepam nasal spray) as an acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from an individual's usual seizure pattern in adult and pediatric patients 6 years of age and older. VALTOCO is a proprietary formulation of diazepam incorporating the science of INTRAVAIL®. Intravail's transmucosal absorption enhancement technology enables the noninvasive delivery of a broad range of protein, peptide and small-molecule drugs. In its approval of VALTOCO, the U.S. Food and Drug Administration also granted Neurelis Orphan Drug Exclusivity and recognized VALTOCO's intranasal route of administration as a clinically superior contribution to patient care over the previously approved standard-of-care treatment (a rectal gel formulation of diazepam). For more information on VALTOCO, please visit . In addition to VALTOCO, Neurelis is developing NRL-4 as a noninvasive rescue therapy to address the escalation of acute agitation symptoms associated with schizophrenia and bipolar 1 mania in adults. In addition, Neurelis is developing NRL-1049 (previously known as BA-1049), an investigational, pre-clinical stage small molecule Rho kinase (ROCK) inhibitor, for the treatment of cerebral cavernous malformations (CCMS), a rare disorder of the central nervous system (CNS). For more information on Neurelis, please visit . For the latest scientific information on VALTOCO, please visit . Important Safety Information about VALTOCO: Indication VALTOCO® (diazepam nasal spray) is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 6 years of age and older. WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation. The use of benzodiazepines, including VALTOCO, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing VALTOCO and throughout treatment, assess each patient's risk for abuse, misuse, and addiction. The continued use of benzodiazepines may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Although VALTOCO is indicated only for intermittent use, if used more frequently than recommended, abrupt discontinuation or rapid dosage reduction of VALTOCO may precipitate acute withdrawal reactions, which can be life-threatening. For patients using VALTOCO more frequently than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue VALTOCO. Contraindications: VALTOCO is contraindicated in patients with: Hypersensitivity to diazepam Central Nervous System (CNS) Depression Benzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness, such as operating machinery, driving a motor vehicle, or riding a bicycle, until the effects of the drug, such as drowsiness, have subsided, and as their medical condition permits. The potential for a synergistic CNS-depressant effect when VALTOCO is used with alcohol or other CNS depressants must be considered, and appropriate recommendations made to the patient and/or care partner. Suicidal Behavior and Ideation Antiepileptic drugs (AEDs), including VALTOCO, increase the risk of suicidal ideation and behavior. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or unusual changes in mood or behavior. Glaucoma Benzodiazepines, including VALTOCO, can increase intraocular pressure in patients with glaucoma. VALTOCO may be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. VALTOCO is contraindicated in patients with narrow-angle glaucoma. Neonatal Sedation and Withdrawal Syndrome Use of VALTOCO late in pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) and/or withdrawal symptoms (hyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties) in the neonate. Monitor neonates exposed to VALTOCO during pregnancy or labor for signs of sedation and monitor neonates exposed to VALTOCO during pregnancy for signs of withdrawal; manage these neonates accordingly. Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preservative VALTOCO is not approved for use in neonates or infants. Serious and fatal adverse reactions, including "gasping syndrome," can occur in neonates and low-birth-weight infants treated with benzyl alcohol–preserved drugs, including VALTOCO. The "gasping syndrome" is characterized by central nervous system depression, metabolic acidosis, and gasping respirations. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known. Adverse Reactions Diazepam, the active ingredient in VALTOCO, is a Schedule IV controlled substance. To report SUSPECTED ADVERSE REACTIONS, contact Neurelis, Inc. at 1-866-696-3873 or FDA at 1-800-FDA-1088 ( ). Please read full Prescribing Information , including Boxed Warning, for additional important safety information. Contacts:

Neurelis Frequently Asked Questions (FAQ)

  • When was Neurelis founded?

    Neurelis was founded in 2007.

  • Where is Neurelis's headquarters?

    Neurelis's headquarters is located at 3430 Carmel Mountain Road, Suite 300, San Diego.

  • What is Neurelis's latest funding round?

    Neurelis's latest funding round is Loan.

  • How much did Neurelis raise?

    Neurelis raised a total of $286.84M.

  • Who are the investors of Neurelis?

    Investors of Neurelis include OrbiMed Advisors, LYZZ Capital, Hale BioPharma Ventures, Decheng Capital, Cormorant Asset Management and 4 more.

  • Who are Neurelis's competitors?

    Competitors of Neurelis include Pozen, Meritage Pharma, Questcor Pharmaceuticals, Cytochroma, Somaxon Pharmaceuticals, Ikano Therapeutics, Adams Respiratory Therapeutics, Intranasal Therapeutics, NeuroMolecular Pharmaceuticals, Shire Pharmaceuticals Group and 13 more.

Compare Neurelis to Competitors

Ikano Therapeutics

Ikano Therapeutics is a specialty pharmaceutical company focused on developing nasally delivered pharmaceutical products with a particular focus on drugs treating pain and disorders related to the central nervous system.

Nano-Mite Technologies

Nano-Mite Technologies is engaged in R&D to control obesity using nanotechnology that alters the body's metabolic rate and increase the cell's ability to convert sugar to energy. Per the company, Nano-Mite's technnology could lead to futures in the treatment of traumatic central nervous system damage and neurodegenerative disorders.


Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.

Q Therapeutics

Q Therapeutics, Inc. is developing glial cell-based therapeutic products for central nervous system disorders in which a disease or injury inhibits normal myelin growth and enzyme performance.


The company is engaged in developing and commercializing drugs for the hospital-based treatment of central nervous system (CNS) disorders and thrombotic/cardiovascular diseases, indications for which there is a substantial unmet medical need.

Richwood Pharmaceutical

Richwood develops drugs for disorders of the central nervous system, particularly hyperactivity in children.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.